Rhumbline Advisers Allakos Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.0 - $1.45 $65,442 - $94,890	-65,442 Reduced 63.21%	38,096 $38,000
Q1 2024 May 09, 2024	BUY	$1.02 - $3.23 $3,530 - $11,179	3,461 Added 3.46%	103,538 $130,000
Q4 2023 Feb 08, 2024	SELL	$1.72 - $3.18 $1,505 - $2,782	-875 Reduced 0.87%	100,077 $273,000
Q3 2023 Nov 09, 2023	SELL	$2.13 - $5.55 $3,810 - $9,928	-1,789 Reduced 1.74%	100,952 $229,000
Q2 2023 Aug 08, 2023	BUY	$3.6 - $5.25 $369,867 - $539,390	102,741 New	102,741 $447,000
Q2 2022 Aug 11, 2022	SELL	$2.6 - $6.14 $93,870 - $221,678	-36,104 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$5.08 - $9.81 $2,733 - $5,277	-538 Reduced 1.47%	36,104 $206,000
Q4 2021 Feb 10, 2022	BUY	$8.55 - $111.89 $2,026 - $26,517	237 Added 0.65%	36,642 $359,000
Q3 2021 Nov 12, 2021	BUY	$76.53 - $110.43 $41,861 - $60,405	547 Added 1.53%	36,405 $3.85 Million
Q2 2021 Aug 05, 2021	BUY	$85.37 - $114.1 $610,822 - $816,385	7,155 Added 24.93%	35,858 $3.06 Million
Q1 2021 May 06, 2021	SELL	$109.73 - $153.66 $347,514 - $486,641	-3,167 Reduced 9.94%	28,703 $3.3 Million
Q4 2020 Feb 10, 2021	BUY	$79.58 - $152.45 $123,587 - $236,754	1,553 Added 5.12%	31,870 $4.46 Million
Q3 2020 Nov 12, 2020	SELL	$66.43 - $90.99 $402,233 - $550,944	-6,055 Reduced 16.65%	30,317 $2.47 Million
Q2 2020 Aug 13, 2020	BUY	$44.04 - $80.69 $416,398 - $762,923	9,455 Added 35.13%	36,372 $2.61 Million
Q1 2020 May 06, 2020	BUY	$44.49 - $93.39 $38,706 - $81,249	870 Added 3.34%	26,917 $1.2 Million
Q4 2019 Feb 05, 2020	BUY	$66.49 - $137.73 $78,657 - $162,934	1,183 Added 4.76%	26,047 $2.48 Million
Q3 2019 Oct 23, 2019	BUY	$31.0 - $89.73 $89,683 - $259,588	2,893 Added 13.17%	24,864 $1.96 Million
Q2 2019 Aug 14, 2019	BUY	$36.0 - $44.73 $121,644 - $151,142	3,379 Added 18.17%	21,971 $952,000
Q1 2019 May 01, 2019	BUY	$33.79 - $51.99 $229,501 - $353,116	6,792 Added 57.56%	18,592 $753,000
Q4 2018 Jan 31, 2019	BUY	$31.59 - $62.65 $172,955 - $343,008	5,475 Added 86.56%	11,800 $617,000
Q3 2018 Nov 07, 2018	BUY	$31.25 - $47.64 $197,656 - $301,323	6,325 New	6,325 $285,000

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

Bvf Inc San Francisco, CA

16.6M
Shares

$21 Million
0.34% of portfolio
Nea Management Company, LLC Timonium, MD

6.15M
Shares

$7.81 Million
0.31% of portfolio
Deep Track Capital, LP Greenwich, CT

5M
Shares

$6.35 Million
0.12% of portfolio
Vanguard Group Inc Valley Forge, PA

3.51M
Shares

$4.46 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

3.08M
Shares

$3.91 Million
0.13% of portfolio

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account